The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease

Chun Jen Lin; Chih Ping Chung; Nien Chen Liao; Po Lin Chen; Nai Fang Chi; Yen Jun Lai; Chih Wei Tang; Chia Hung Wu; Feng Chi Chang; Chao Bao Luo; Li Yu Fay; Chun Fu Lin; Chung Hsing Chou; Tsong Hai Lee; Jiunn Tay Lee; Jiann Shing Jeng; I. Hui Lee

doi:10.1097/JCMA.0000000000000952

The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease

Chun Jen Lin, Chih Ping Chung, Nien Chen Liao, Po Lin Chen, Nai Fang Chi, Yen Jun Lai, Chih Wei Tang, Chia Hung Wu, Feng Chi Chang, Chao Bao Luo, Li Yu Fay, Chun Fu Lin, Chung Hsing Chou, Tsong Hai Lee, Jiunn Tay Lee, Jiann Shing Jeng, I. Hui Lee^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.

Original language	English
Pages (from-to)	697-714
Number of pages	18
Journal	Journal of the Chinese Medical Association
Volume	86
Issue number	8
DOIs	https://doi.org/10.1097/JCMA.0000000000000952
State	Published - 1 Aug 2023

Keywords

Anticoagulants
Antiplatelets
Intracranial atherosclerotic disease
Stenting
Stroke
Thrombectomy

Access to Document

10.1097/JCMA.0000000000000952

Cite this

Lin, C. J., Chung, C. P., Liao, N. C., Chen, P. L., Chi, N. F., Lai, Y. J., Tang, C. W., Wu, C. H., Chang, F. C., Luo, C. B., Fay, L. Y., Lin, C. F., Chou, C. H., Lee, T. H., Lee, J. T., Jeng, J. S., & Lee, I. H. (2023). The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease. Journal of the Chinese Medical Association, 86(8), 697-714. https://doi.org/10.1097/JCMA.0000000000000952

@article{4a279c28b49d4c6b8883c9d54cf5fd18,

title = "The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease",

abstract = "Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.",

keywords = "Anticoagulants, Antiplatelets, Intracranial atherosclerotic disease, Stenting, Stroke, Thrombectomy",

author = "Lin, {Chun Jen} and Chung, {Chih Ping} and Liao, {Nien Chen} and Chen, {Po Lin} and Chi, {Nai Fang} and Lai, {Yen Jun} and Tang, {Chih Wei} and Wu, {Chia Hung} and Chang, {Feng Chi} and Luo, {Chao Bao} and Fay, {Li Yu} and Lin, {Chun Fu} and Chou, {Chung Hsing} and Lee, {Tsong Hai} and Lee, {Jiunn Tay} and Jeng, {Jiann Shing} and Lee, {I. Hui}",

year = "2023",

month = aug,

day = "1",

doi = "10.1097/JCMA.0000000000000952",

language = "English",

volume = "86",

pages = "697--714",

journal = "Journal of the Chinese Medical Association",

issn = "1726-4901",

publisher = "Elsevier Taiwan LLC",

number = "8",

}

Lin, CJ, Chung, CP, Liao, NC, Chen, PL , Chi, NF, Lai, YJ, Tang, CW, Wu, CH, Chang, FC, Luo, CB, Fay, LY, Lin, CF, Chou, CH, Lee, TH, Lee, JT, Jeng, JS & Lee, IH 2023, 'The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease', Journal of the Chinese Medical Association, vol. 86, no. 8, pp. 697-714. https://doi.org/10.1097/JCMA.0000000000000952

TY - JOUR

T1 - The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease

AU - Lin, Chun Jen

AU - Chung, Chih Ping

AU - Liao, Nien Chen

AU - Chen, Po Lin

AU - Chi, Nai Fang

AU - Lai, Yen Jun

AU - Tang, Chih Wei

AU - Wu, Chia Hung

AU - Chang, Feng Chi

AU - Luo, Chao Bao

AU - Fay, Li Yu

AU - Lin, Chun Fu

AU - Chou, Chung Hsing

AU - Lee, Tsong Hai

AU - Lee, Jiunn Tay

AU - Jeng, Jiann Shing

AU - Lee, I. Hui

PY - 2023/8/1

Y1 - 2023/8/1

N2 - Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.

AB - Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, especially in Asian populations, which has a high risk of recurrent stroke and cardiovascular comorbidities. The present guidelines aim to provide updated evidence-based recommendations for diagnosis and management of patients with ICAD. Taiwan Stroke Society guideline consensus group developed recommendations for management of patients with ICAD via consensus meetings based on updated evidences. Each proposed class of recommendation and level of evidence was approved by all members of the group. The guidelines cover six topics, including (1) epidemiology and diagnostic evaluation of ICAD, (2) nonpharmacological management of ICAD, (3) medical therapy for symptomatic ICAD, (4) endovascular thrombectomy and rescue therapy for acute ischemic stroke with underlying ICAD, (5) endovascular interventional therapy for postacute symptomatic intracranial arterial stenosis, and (6) surgical treatment of chronic symptomatic intracranial arterial stenosis. Intensive medical treatment including antiplatelet therapy, risk factor control, and life style modification are essential for patients with ICAD.

KW - Anticoagulants

KW - Antiplatelets

KW - Intracranial atherosclerotic disease

KW - Stenting

KW - Stroke

KW - Thrombectomy

UR - http://www.scopus.com/inward/record.url?scp=85167843037&partnerID=8YFLogxK

U2 - 10.1097/JCMA.0000000000000952

DO - 10.1097/JCMA.0000000000000952

M3 - Article

C2 - 37341526

AN - SCOPUS:85167843037

SN - 1726-4901

VL - 86

SP - 697

EP - 714

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

IS - 8

ER -

The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this